family with sequence similarity 174 member BGenealiases: []
Q-omics provides the consensus-scored FAM174B profile across patient tissues and cancer cell-line models. FAM174B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FAM174B is differentially expressed in 13, with the highest sampling consensus in LUSC. Additionally, FAM174B RNA expression shows 16,443 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight SKCM, LUSC, and BRCA as cancer lineages where FAM174B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM174B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM174B survival associations across molecular data types. FAM174B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM174B RNA expression–survival associations across cancer types. High FAM174B expression shows unfavorable associations in SKCM and UVM, but favorable associations in UCEC, KIRC, BLCA and THCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FAM174B RNA expression.
This table summarizes FAM174B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM174B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM174B shows lower tumor expression in LUSC and LUAD and higher tumor expression in BRCA, LIHC, CHOL and KICH. The LUSC box plot shows higher FAM174B RNA expression in normal versus tumor tissue (log2 FC = −2.594, t-test p < 0.001).
This table shows molecular features associated with FAM174B in patient tissues and cancer cell lines. In patient samples, FAM174B shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM174B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
